of 1995, no perso

FORM

PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031

ons		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE lection of information unless it displays a valid OMB control number.
	Application Number	10/750,996
	Filing Date	December 31, 2003
	First Named Inventor	Antoni kozlowski et al.
	Art Unit	1626
	Examiner Name	Unknown
	Attorney Docket Number	SHE0065.00

(to be used for all correspondence after initia	Examinor Hamo	Unknown				
Total Number of Pages in This Submission	Attorney Docket Number	SHE00	65.00			
ENCLOSURES (Check all that apply)						
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request X Information Disclosure Statement		Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Terminal Disclaimer Request for Refund CD, Number of CD(s)	on Address	After Allowance Communication to TC Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter X Other Enclosure(s) (please Identify below): 17 Cited References		
Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53	Rema	Landscape Table on C	D			
SIGNA	TURE	OF APPLICANT, ATTO	RNEY, C	OR AGENT		
Firm Name NEKTAR THERA			·			
Signature Susan	1.E1	rans				
Printed name Susan T. Evans						
Date 10-08-04			Reg. No.	38,443		
CERTIFICATE OF TRANSMISSION/MAILING						
I pereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:						
Signature Mun	na	Cotta				
Typed or printed name Minna Cotte		-		Date 12 OCT 04		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents. P.O. Box 1450, Alexandria, VA 22313-1450. ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Antoni Kozlowski et al.)

Application No.: 10/750,996

Filed: 12/31/2003

Title: MALEAMIC ACID POLYMER

DERIVATIVES AND THEIR

BIOCONJUGATES

Atty. Docket No.: SHE0065.00

Examiner: Unassigned

Group Art Unit: 1626

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, Virginia 22313-1450 on

gned: Minia C

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56, §1.97 and §1.98

Assistant Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

The references listed in the attached Forms PTO/SB/08A and B may be material to examination of the above-identified patent application. Applicants submit these references in compliance with their duty of disclosure pursuant to 37 CFR §§1.56, 1.97, and 1.98. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

Copies of the references are enclosed, as required under 37 CFR §§1.98.

This Information Disclosure Statement is being timely filed under 37 CFR §§1.97 and is being filed:

Attorney Docket No. SHE0065.00

	within three months of the filing date of a national application or an RCE; within months of the date of entry of the national stage as set forth in section 1.491 in an international application; or before the mailing date of a first Office action on the merits (whichever event occurs last);	ì				
	Please charge the amount of \$ to Deposit Account 500348					
\boxtimes	If it is determined that any additional fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account 500348.					
	Respectfully submitted,					
	NEKTAR THERAPEUTICS					
Dated:	October 8, 2004 By: Susan T. Evans Reg. No. 38,443	•				

01,6		
Form PTO/SB/08A (Modified)	Atty Docket No.:	Application No.:
OCT 1 3 2004	SHE0065.00	10/750,996
Information Bisclosure	Applicant:	
Statement By Applicant		ozlowski et al.
	Filing Date:	Group:
(Use Several Sheets if Necessary)	12/31/2003	1626

U.S. Patent Documents

Examiner						Sub-	Filing
Initial	No.	Patent No.	Date	Patentee	Class	Class	Date
	Α	5,585,484	12/17/1996	Acharya et al.			
	В	5,766,897	06/16/1998	Braxton	1		
	С	5,932,462	08/03/1999	Harris et al.			
	D	6,180,134	01/30/2001	Zalipsky et al.	<u> </u>		
	Е	6,180,598	01/30/2001	Nelson			
	F	6,183,738	02/06/2001	Clark			
	G	6,602,498	08/05/2003	Shen			
	Н	2001/0044526	11/22/2001	Shen			
	I	2003/0065134	04/03/2003	Sakanoue et al.			
	Ì						
		,					
`			-			, , , , , ,	
, ,				=			
				,,,			-
				,			
					1		
					†		

· · · · · · · · · · · · · · · · · · ·		
Examiner:	Date Considered:	

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO/SB/08A (Modified)	Atty Docket No.:	Application No.:	
	SHE0065.00	10/750,996	
Information Disclosure	Applicant:		
Statement By Applicant	Antoni Kozlowski et al.		
	Filing Date:	Group:	
(Use Several Sheets if Necessary)	12/31/2003	1626	

Foreign Patent or Published Foreign Patent Application

Examiner		Document	Publication	Country or		Sub-	Trans	lation
Initial	No.	No.	Date	Patent Office	Class	class	Yes	No
	J	0 318 162	05/31/1989	EP				
	K	1 283 233	02/12/2003	EP				
	L	99/64460	12/16/1999	WO				
	M	00/21594	04/20/2000	WO				
	N	01/62827	08/30/2001	wo				
					-	-		
			_			-		
						<u>-</u>		

Examiner:	Date Considered:
Examiner.	Date Considered:
	· · · · · · · · · · · · · · · · · · ·

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO/SB/08B (Modified)	Atty Docket No.:	Application No.:	
	SHE0065.00	10/750,996	
Information Disclosure	Applicant:		
Statement By Applicant	Antoni Kozlowski et al.		
	Filing Date:	Group:	
(Use Several Sheets if Necessary)	12/31/2003	1626	

Other Documents

Examiner		
Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
	0	KOGAN, "The Synthesis of Substituted Methoxy-Poly(Ethyleneglycol) Derivatives Suitable for Selective Protein Modification", Synthetic Communications (1992), Vol. 22, No. 16, pp. 2417-2424.
	P	ROBERTS ET AL., "Chemistry for peptide and protein PEGylation", Advanced Drug Delivery Reviews (2002), Vol. 54, pp. 459-476.
	Q	VERONESE, "Peptide and protein PEGylation: a review of problem and solutions", Biomaterials (2001), Vol. 22, pp. 405-417.
	,	

Examiner:	Date Considered:

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.